In May of 2022, Rapidemic’s research team has created its first functional proof-of-concept for their groundbreaking platform technology for decentralized nucleic acid detection. The molecular test comprises a DNA amplification reaction, coupled to an easy, universal read-out method. The novelty of the test lies in the ability to increaser the sensitivity and specificity of the reactions, while minimizing the risk of false positives. This is a milestone in the development of the technology, which forms a basis for further development. Going forward, the team will focus on integrating this proof-of-concept into a first prototype of the product. Team will also kick off the first tests of the technology using patient urine samples.